BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Zacks Investment Research
BillionToOne (BLLN) Reports Next Week: Wall Street Expects Earnings GrowthBillionToOne (BLLN) is set to report Q3 2026 earnings on November 4, with Wall Street expecting 60% YoY EPS growth to $0.16 and 39.2% revenue growth to $116.23 million. However, the stock carries a negative Earnings ESP of -3.23% and a Zacks Rank #4 (Sell), making it unlikely to beat consensus estimates. The company has beaten EPS estimates only twice in the last four quarters.
Headlines open the publisher's site.
